Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility

Alector, Inc.

2026-Q1 EPS reported -$0.21 revenue$1,046,000

Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.
Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.
Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.
ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.
R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.